Plasma levels of human atrial natriuretic peptide in patients with hypertensive diseases

Ito, Osamu; Shimamoto, Kazuaki; Ando, Toshiaki; Ura, Nobuyuki; Ishida, Hiroyuki; Nakagawa, M.; Yokoyama, Takahiro; Fukuyama, Shuzaburo; Yamaguchi, Y; Yamaji, Izumi

doi:10.1139/y87-267

Cited by 14 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence is accumulating for a pathophysiological role for ANF in hypertension. Indeed, elevated plasma ANF levels have been described in patients with essential hypertension, primary aldosteronism, chronic renal failure and malignant hypertension (Jimura, Shimamoto, Ando, Ura, Ishida, Nakagawa, Yokoyama, Fukuyama, Yamaguchi & Yamaji, 1987), and in some animal hypertensive models including spontaneously hypertensive rats (SHRs) and stroke-prone SHRs (Morii, Nakao, Kihara, Sugawara, Sakamoto, Yamori & Imura, 1986b). In contrast, ANF concentrations in the atria, ventricles and in certain brain areas (subfornical organ, paraventricular hypothalamic nuclei and arcuate nuclei) are decreased in hypertensive rats (Morii et al 1986a;Saavedra, 1987;Bahner, Geiger, Palkovits & Heidland, 1988).…”

Section: Introductionmentioning

confidence: 99%

Central and peripheral effects of the peptide ANF on renal function and blood pressure in hypertensive rats.

Al-Barazanji

Balment

1989

The Journal of Physiology

View full text Add to dashboard Cite

SUMMARY1. The present study assesses renal and blood pressure effects of systemically and intracerebroventricularly (I.c.v.) administered atrial natriuretic factor (ANF) in anaesthetized New Zealand genetically hypertensive (NZGH) rats and their normotensive substrain (NZN).2. Plasma ANF concentration was significantly raised in NZGH compared with NZN animals. Intravenous ANF administration increased circulating ANF concentration to similar levels in NZGH and NZN rats. Plasma aldosterone concentrations were initially similar in normotensive and hypertensive animals and were reduced markedly by i.v. ANF administration in both groups.3. Peripheral administration of ANF produced a significant and sustained hypotension during the period of the hormone administration in NZGH animals, while arterial mean blood pressure (MBP) was not altered significantly in NZN rats. Central infusion of ANF produced no change in MBP in either NZGH or NZN animals. There was no detectable change in heart rate during central or peripheral administration of the hormone in either group.4. By comparison with animals maintained on hormone-free infusate, urine flow changed little over the 80 min period of i.v. ANF infusion in NZGH r"t,s but was markedly increased in NZN animals. Urinary sodium excretion was elei .-ted during ANF infusion in both NZGH and NZN animals. Central infusion of Al F produced a diuresis in NZN rats but a slight reduction in urine flow in NZGH animals, while sodium excretion was not affected in either group. 5. It appears from the present study that central and peripheral ANF effects on renal function and blood pressure differ in hypertensive and normotensive animals. These differences may in part reflect adjustments to long-term elevation in plasma ANF in hypertension and in part are possibly associated with disturbances in related endocrine mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Central and peripheral effects of the peptide ANF on renal function and blood pressure in hypertensive rats.

Al-Barazanji

Balment

1989

The Journal of Physiology

View full text Add to dashboard Cite

show abstract

“…Our recent studies in the Brattleboro rats indicate that the influence of vasopressin on plasma ANP is perhaps more closely related to the resultant fluid balance than any specific action of vasopressin directly on ANP secretion (Burgess & Balment, 1992). Iimura et al (1987) considered the high ANP levels, which characterized patients with essential hypertension, as a secondary or compensatory reaction to high blood pressure.…”

Section: Discussionmentioning

confidence: 99%

Renal, endocrine and vascular effects of atrial natriuretic peptide in a novel vasopressin‐deficient genetically hypertensive strain of rat

al-Barazanji¹,

Balment²

1995

Experimental Physiology

View full text Add to dashboard Cite

SUMMARYIn the absence of the potentially confounding influence of vasopressin in hypertension, the effects of atrial natriuretic peptide (ANP) on arterial blood pressure and renal handling of water and sodium were assessed from comparison of responses to intravenous ANP infusion in anaesthetized vasopressin-deficient New Zealand genetically hypertensive (DI/H) rats and their normotensive substrain (DI/N). After 320 min of hypotonic saline infusion, plasma ANP concentration was significantly higher in DI/H compared with DI/N rats. ANP administration increased circulating ANP concentration in both groups. Plasma angiotensin II concentration was higher in DI/H than in DI/N rats; infusion of ANP raised circulating angiotensin II in both groups though this achieved statistical significance only in DI/N rats. Plasma aldosterone concentrations were initially similar in normotensive and hypertensive animals and, in both, were reduced markedly by i.v. ANP infusion. Administration of ANP produced sustained hypotension in both groups. However, the hypotensive effect of ANP was more pronounced in DI/H compared with DI/N rats. Heart rate was initially similar in the two groups, and infusion of ANP produced no detectable change. By comparison with animals maintained on hormone-free infusate, urine flow increased markedly over the 80 min period of ANP infusion in both groups, by 142 % in DI/H rats and 127 % in DI/N rats. ANP administration produced a natriuresis in both groups but the increase in Na+ excretion was much greater in DI/H (342 %) than in DI/N (139 %) rats. It appears from the current study that vasopressin-deficient hypertensive rats are more sensitive to ANP with regard to effects on blood pressure and renal excretion than their vasopressin-deficient normotensive substrain. These differences may, in part, reflect adjustments to long-term elevation in blood pressure and in plasma ANP concentration in hypertension and, in part, rely on the associated disturbances in related endocrine systems.

show abstract

“…Production of multiple oligopeptide forms was later shown to be rather a common phenomenon, for example, for somatostatin [16 18], atrial natriuretic peptide [19,20], etc. Therefore, thousands of the known oligopeptides probably also exist in multiple forms, but these forms are not yet identified.…”

Section: Biogenesismentioning

confidence: 99%

Biochemical problems of regulation by oligopeptides

Zamyatnin

2004

Biochemistry (Moscow)

View full text Add to dashboard Cite

Some problems are considered which arise in biochemical studies on structure and function of natural oligopeptides consisting of 2-50 amino acid residues. The problems under consideration include the generation of oligopeptides from precursors, chemical structure, the role of functionally important radicals and spatial configuration, and structure-function relationships. Different types of regulation are shown mainly for oligopeptides involved in muscle contraction.

show abstract

Plasma levels of human atrial natriuretic peptide in patients with hypertensive diseases

Cited by 14 publications

References 15 publications

Central and peripheral effects of the peptide ANF on renal function and blood pressure in hypertensive rats.

Central and peripheral effects of the peptide ANF on renal function and blood pressure in hypertensive rats.

Renal, endocrine and vascular effects of atrial natriuretic peptide in a novel vasopressin‐deficient genetically hypertensive strain of rat

Biochemical problems of regulation by oligopeptides

Contact Info

Product

Resources

About